Concepedia

Maya Ridinger

MR

Statistics

Publications

10

Citations

382

H-Index

10

Active since

1987

Affiliations

San Diego Composites (United States)(Current)

Mayo Clinic in Arizona

City of Hope

Mayo Clinic Hospital

Maya Ridinger is an author at San Diego Composites (United States) specializing in medicine, pharmacology, and polo-like kinase inhibition.

ORCID

Publications per year

1987–2024

10

Publications

10

A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Amer M. Zeidan, Maya Ridinger, Tara L. Lin et al. · Clinical Cancer Research · 2020 · 89 citations · Full text

, , +17

Endothelium-dependent gender differences in the response of the rat aorta.

Yvonne T. Maddox, J G Falcon, Maya Ridinger et al. · Journal of Pharmacology and Experimental Therapeutics · 1987 · 47 citations

, , +9

Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of <i>KRAS</i> -Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study

Daniel H. Ahn, Afsaneh Barzi, Maya Ridinger et al. · Clinical Cancer Research · 2024 · 47 citations · Full text

, , +17

Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer

Antonio Giordano, Yueying Liu, Kent Armeson et al. · PLoS ONE · 2019 · 45 citations · Full text

, , +16

A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy

Dong Wang, Bethany Veo, Angela Pierce et al. · Neuro-Oncology · 2021 · 44 citations · Full text

, , +16

1–5 of 10